Skip to main content
Clinical Trials/NCT04186975
NCT04186975
Unknown
Not Applicable

Computerized Antepartum Monitoring Using Non-invasive Fetal Ecg for High Risk Pregnancy

Rambam Health Care Campus0 sites500 target enrollmentDecember 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiotocography
Sponsor
Rambam Health Care Campus
Enrollment
500
Primary Endpoint
Comparison between computerized CTG and NI-FECG
Last Updated
6 years ago

Overview

Brief Summary

The long term aim of this research is to evaluate a portable NI-FECG (Non-invasive fetal ECG) monitor (Holter NI-FECG) which can be used for regular remote assessment of fetal health in pregnancies at risk or to follow-up on treatments. The elaboration of a NI-FECG Holter device will offer new opportunities for fetal diagnosis and remote monitoring of problematic pregnancies because of its low-cost, non-invasiveness, portability and minimal set-up requirements.

Detailed Description

Pregnant patients that are of gestational age in which fetal heart rate monitoring is recommended and feasible will be enrolled to this cohort study. Each patient will be monitored via conventional fetal heart rate monitoring in addition to the NI-FECG method and both methods will be directly compared. Each patient will be her own control. NI-FECG is a non-invasive method of fetal monitoring' thus no ethical issues are relevant. Nevertheless, each patient will sign informed consent before participating in the study.

Registry
clinicaltrials.gov
Start Date
December 1, 2019
End Date
December 1, 2023
Last Updated
6 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Oren Grunwald MD

Oren Grunwald MD

Rambam Health Care Campus

Eligibility Criteria

Inclusion Criteria

  • Singleton pregnancies.
  • low-risk pregnancy: women from the post-date clinic (after 40 weeks' gestation) in which we perform routinely Non stress test and ultrasound.
  • High-risk pregnancy: women who are hospitalized for different indications: IUGR, diabetes, hypertension, non-reassuring fetal heart rate, Decreased fetal movements

Exclusion Criteria

  • Non singleton pregnancies.
  • Do not want to participate in the study

Outcomes

Primary Outcomes

Comparison between computerized CTG and NI-FECG

Time Frame: 4 years

To compare the predictive power of computerized CTG versus computerized NI-FECG for the assessment of abnormal traces. For that purpose, a machine learning model will be trained (1) on features extracted from the FHR trace obtained using CTG and (2) on features extracted from the FHR obtained using the NI-FECG trace

Identification of abnormal fetal heart rate from NI-FECG

Time Frame: 2 years

To compare the clinical interpretation of the NI-FECG obtained fetal heart rate trace to the fetal heart rate interpretation from the fetal heart rate obtained from conventional CTG. This will involve blinded reading and scoring of FHR obtained from the NI-FECG and CTG from a panel of expert clinician.

Computerized NI-FECG for the prediction of abnormal FHR traces

Time Frame: 2 years

To compare the computerized analysis of the FHR trace obtained using NI-FECG to the clinician visual interpretation of the FHR trace obtained using CTG (usual care). This will involve the implementation of algorithms that can detect standard14 and new features assessing the Fetal HRV (FHRV) and the elaboration of a machine learning model which can predict abnormal traces from these features

Develop a portable NI-FECG monitor for remote fetal monitoring.

Time Frame: 4 years

To develop a portable NI-FECG monitor which can be used to record the fetal ECG at the patient's home. The monitor will transfer the data to a remote server where source separation will be performed to extract the fetal ECG. Algorithms implemented for extracting characteristic features and the machine learning model will be run to predict whether the traces are normal or abnormal. The elaboration of such algorithm is particularly relevant for resource constrained region where medical experts is scarce.

Similar Trials